scholarly journals Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression

2004 ◽  
Vol 50 (7) ◽  
pp. 2264-2272 ◽  
Author(s):  
Philip J. Mease ◽  
Alan J. Kivitz ◽  
Francis X. Burch ◽  
Evan L. Siegel ◽  
Stanley B. Cohen ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Disease Progression ◽  
Etanercept Treatment

Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis

2010 ◽  
Vol 13 (2) ◽  
pp. 228-235 ◽  
Author(s):  
Sarah Thayer ◽  
Crystal Watson ◽  
Rui Song ◽  
Denise R. Globe ◽  
David J. Harrison
Keyword(s):  
Psoriatic Arthritis ◽  
Managed Care ◽  
Treatment Patterns ◽  
Etanercept Treatment

Determination of Lymphotoxin-Alpha Levels in Patients with Psoriatic Arthritis Undergoing Etanercept Treatment

2012 ◽  
Vol 32 (6) ◽  
pp. 277-279 ◽  
Author(s):  
Giuseppe Murdaca ◽  
Barbara Maria Colombo ◽  
Paola Contini ◽  
Francesco Puppo
Keyword(s):  
Psoriatic Arthritis ◽  
Etanercept Treatment ◽  
Lymphotoxin Alpha

scholarly journals The Relationship between HLA-B27, HLA-Cw06, HLA-DR7 and Psoriatic Arthritis in Vietnamese Patients: Disease Progression and Therapeutic Burden

2019 ◽  
Vol 7 (2) ◽  
pp. 300-301
Author(s):  
Vinh Ngo Minh ◽  
Van Bui Thi ◽  
Tro Chau Van ◽  
Trai Nguyen Ngoc ◽  
Anh Tran Ngoc ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Disease Progression ◽  
Plaque Psoriasis ◽  
Cross Sectional Study ◽  
Ho Chi Minh City ◽  
City Hospital ◽  
Hla B27 ◽  
Cross Sectional ◽  
Severe Arthritis ◽  
The Relationship

We conducted a prospective, cross-sectional study at Ho Chi Minh City Hospital of Dermato Venereology from January 2016 to March 2017 in 40 psoriatic arthritis (PsA) patients to evaluate the disease progression and therapeutic burden about the HLA patterns. Based upon our results, PsA with HLA-B27 (+) had a threat of severe arthritis. PsA with HLA-Cw06 (+) had a higher risk of earlier onset and shorter duration for plaque psoriasis to transform into PsA. HLA-DR7 (+) in PsA delayed the time for conversion from plaque psoriasis into PsA. These findings are quite similar to other studies in the literature.

scholarly journals THE CASE OF PSORIATIC ERYTHRODERMA AND SEVERE COMORBID PSORIATIC ARTHRITIS

2019 ◽  
Vol 22 (1-2) ◽  
pp. 15-23
Author(s):  
O. Yu Olisova ◽  
N. G Kochergin ◽  
T. A Belousova ◽  
Victoria O. Nikuradze ◽  
V. V Gudova
Keyword(s):  
Psoriatic Arthritis ◽  
Early Diagnosis ◽  
Disease Progression ◽  
Systemic Therapy ◽  
Biological Agents ◽  
Severe Psoriasis ◽  
Early Initiation ◽  
Main Role ◽  
Treatment And Prevention ◽  
Timely Treatment

Early diagnosis of psoriatic arthritis (PsA) is necessary for timely treatment and prevention of the disease progression with destruction of the joints. In most patients, comorbid PsA develops many years after the debut of the skin process. Consequently, the main role in timely diagnosis of PsA is played by a dermatologist, who is able to identify its initial signs and refer the patient to a rheumatologist. Early initiation of systemic therapy with the use of modern biological agents for progressive psoriatic arthritis and severe psoriasis can prevent the development of irreversible disability.

PP36 Early Diagnosis And Treatment Of Psoriatic Arthritis

2018 ◽  
Vol 34 (S1) ◽  
pp. 79-80
Author(s):  
Nicolas Iragorri ◽  
Eldon Spackman
Keyword(s):  
Psoriatic Arthritis ◽  
Cost Effectiveness ◽  
Disease Progression ◽  
Biologic Therapy ◽  
Cost Effective ◽  
Screening Tools ◽  
Test Accuracy ◽  
Life Years ◽  
Cost Effectiveness Threshold ◽  
Effectiveness Threshold

Introduction:Screening for psoriatic arthritis (PsA) is expected to identify patients at earlier stages of the disease. Early treatment is expected to slow disease progression and delay the need for biologic therapy. This study estimated the cost-effectiveness of screening tools for PsA in Canada.Methods:A Markov model was built to estimate the associated costs and quality-adjusted life-years (QALYs) of screening tools for PsA in patients using topical treatment for psoriasis. The screening tools included: the Toronto Psoriatic Arthritis Screening (ToPAS) questionnaire; the Psoriasis Epidemiology Screening Tool (PEST); the Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire; and the Early ARthritis for Psoriatic patients (EARP) questionnaire. Health states were defined by disability levels, as measured by the Health Assessment Questionnaire (HAQ), and state transition was modeled according to annual disease progression. Screening was assumed to be effective during a 2-year sojourn period. Incremental cost-effectiveness ratios (ICERs) were estimated based on health-state specific costs and utilities. A probabilistic analysis was undertaken to account for parameter uncertainty. All results were compared with the commonly cited cost-effectiveness threshold of CAD 50,000 (USD 37, 600) per additional QALY.Results:Screening with the ToPAS questionnaire resulted in cost savings compared with no screening or the EARP questionnaire, with a total cost of CAD 30,706 (USD 23,090) and 17.29 QALYs. The PEST dominated the PASE questionnaire and was more costly and more effective than the ToPAS questionnaire, with an ICER of CAD 312,398 (USD 234,909). The results were most sensitive to test sensitivity and specificity, HAQ progression, and average HAQ score at diagnosis and the start of biologic therapy. A scenario analysis tested screening efficacy for a 1-year period before diagnosis, with the ToPAS questionnaire remaining the most cost-effective option.Conclusions:Screening was cost-effective compared with no screening at the commonly used cost-effectiveness threshold of CAD 50,000 (USD 37, 600). Value of information analyses will be useful for determining the need to collect further information around test accuracy parameters.

Sign in / Sign up

Export Citation Format

Share Document